Friday, June 30, 2023
Biosyngen has announced the opening of its latest Good Manufacturing Practise (GMP) facility in Singapore.
The opening of this GMP facility in Singapore represents a significant advancement in the country's capabilities in the field of cell manufacturing and R&D, particularly within the CGT industry.
This facility will serve as a hub for research and development in drug discovery and process development. It is also designed to accommodate advanced processes and products that may be introduced in the future.
The newly established facility is the first and largest privately owned fully automatic and enclosed integrated GMP cell manufacturing facility and R&D base in Singapore to date. It is compliant with the latest recommendations of the U.S. Food and Drug Administration (FDA), ensuring adherence to high standards. The facility enables Biosyngen to run automatic and closed-system production, which is considered the preferred best practise in the CGT industry.
